CO5160259A1 - Interferon alfa pegilado en la terapia contra el hiv - Google Patents

Interferon alfa pegilado en la terapia contra el hiv

Info

Publication number
CO5160259A1
CO5160259A1 CO00014824A CO00014824A CO5160259A1 CO 5160259 A1 CO5160259 A1 CO 5160259A1 CO 00014824 A CO00014824 A CO 00014824A CO 00014824 A CO00014824 A CO 00014824A CO 5160259 A1 CO5160259 A1 CO 5160259A1
Authority
CO
Colombia
Prior art keywords
therapy against
against hiv
hiv
interferon alfa
pegilado
Prior art date
Application number
CO00014824A
Other languages
English (en)
Inventor
Mark A Laughlin
Paul W Glue
Carlos O Stangis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO5160259A1 publication Critical patent/CO5160259A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen los usos del interferón alfa, solo y en combinación con una farmacoterapia contra el HIV -1 y la ribavirina para la preparación de un medicamento para el tratamiento de pacientes que no han experimentado tratamientos y pacientes adultos y pediátricos infectados por el HIV -1 que han experimentado tratamientos así como pacientes coinfectados con HIV-1 y HCV, que comprende una cantidad terapéuticamente efectiva de interferón alfa pegilado, por ejemplo interferón alfa-2b pegilado, como monoterapia o, preferentemente en combinación con una cantidad terapéuticamente efectiva de por lo menos una entre ribavirina, IL-2, IL-12 y pentafusida sola o en combinación con una cantidad terapéuticamente efectiva de una farmacoterapia contra el HIV-1, por ejemplo HAART.
CO00014824A 1999-03-02 2000-03-01 Interferon alfa pegilado en la terapia contra el hiv CO5160259A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26038899A 1999-03-02 1999-03-02
US26852199A 1999-03-12 1999-03-12
US28835899A 1999-04-08 1999-04-08
US45400499A 1999-12-03 1999-12-03

Publications (1)

Publication Number Publication Date
CO5160259A1 true CO5160259A1 (es) 2002-05-30

Family

ID=27500674

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00014824A CO5160259A1 (es) 1999-03-02 2000-03-01 Interferon alfa pegilado en la terapia contra el hiv

Country Status (8)

Country Link
EP (1) EP1034790A3 (es)
JP (1) JP2000256211A (es)
AR (1) AR029337A1 (es)
AU (1) AU3714800A (es)
CA (1) CA2299893A1 (es)
CO (1) CO5160259A1 (es)
PE (1) PE20001548A1 (es)
WO (1) WO2000051631A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0108997A (pt) * 2000-03-09 2003-06-03 Schering Corp Terapia imune adjuvante para hiv
EP1526872A1 (en) 2002-07-24 2005-05-04 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
PT2061513E (pt) * 2007-09-14 2011-10-17 Schering Corp Método para tratar doentes com hepatite c
EP2455456A1 (en) 2010-11-22 2012-05-23 Institut Curie Use of kinesin inhibitors in HIV infection treatment and a method for screening them
US11180555B2 (en) * 2014-09-16 2021-11-23 Ubi Us Holdings, Llc. Antibodies directed against CD4 for the treatment and functional cure of HIV
CA3033728A1 (en) 2016-08-13 2018-02-22 Ubi Ip Holdings Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0730470B1 (en) * 1993-11-10 2002-03-27 Enzon, Inc. Improved interferon polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases

Also Published As

Publication number Publication date
WO2000051631A2 (en) 2000-09-08
WO2000051631A3 (en) 2001-01-18
EP1034790A3 (en) 2000-12-13
CA2299893A1 (en) 2000-09-02
AU3714800A (en) 2000-09-21
AR029337A1 (es) 2003-06-25
JP2000256211A (ja) 2000-09-19
PE20001548A1 (es) 2001-01-16
EP1034790A2 (en) 2000-09-13

Similar Documents

Publication Publication Date Title
AR023824A1 (es) Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado.
AR023541A1 (es) Terapia de combinacion para vhc
PE119199A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
ES2186714T3 (es) Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
HUP0103423A2 (hu) Ribavirint és alfa-interferont tartalmazó kombinált terápia vírusellenes kezelésben nem részesült, krónikus hepatitis C fertőzött paciensek kezelésében
WO2002034284A3 (en) Methods of therapy for hiv infection
BRPI0418157A (pt) terapêutica de tumores alogênicos
CO5160259A1 (es) Interferon alfa pegilado en la terapia contra el hiv
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
BR0108997A (pt) Terapia imune adjuvante para hiv
ECSP003373A (es) Terapia contra el hiv
EP1185283A4 (en) NEW THERAPEUTIC USE OF A VIRAL INJECTION MODULATING PROTEIN TO PREVENT EXHAUST FROM FOREIGN TRANSPLANTS
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
AR023398A1 (es) Terapia para melanomas
ECSP003462A (es) Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado (caso ino1024k)
AR013498A1 (es) Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa
DE69130571D1 (de) Peptide, die infektionen mit menschlichem immunschwächevirus hemmen und deren anwendungsweisen
IL154299A0 (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
AR023390A1 (es) Terapia para la leucemia mielocitica cronica
PT1150981E (pt) Composto nucleosidico terapeutico
ECSP003446A (es) Terapia de combinacion para vhc
ECSP003419A (es) Terapia para melanomas
ECSP003413A (es) Terapia para la leucemia mielocitica cronica